PDCD1 and acute myeloid leukemia: In AML and MDS, either the level of differentiation, the frequency of CD11b+ blasts, or the expression of PD-1 ligands have been described as critical factors that associate with disease progression and limit the benefit from cancer therapy2,28,38.